TY - JOUR T1 - Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use. A1 - Syed,Yahiya Y, Y1 - 2023/05/03/ PY - 2023/04/13/accepted PY - 2023/5/22/medline PY - 2023/5/3/pubmed PY - 2023/5/3/entrez SP - 369 EP - 377 JF - Clinical drug investigation JO - Clin Drug Investig VL - 43 IS - 5 N2 - Olipudase alfa (Xenpozyme™) is an intravenously administered acid sphingomyelinase enzyme replacement therapy indicated to treat non-CNS manifestations of acid sphingomyelinase deficiency (ASMD) in adult and paediatric patients. It is the first and currently the only disease-modifying treatment for ASMD. Olipudase alfa treatment improves hepatosplenomegaly, lung function and platelet counts, along with multiple other pathological features of ASMD in adult and paediatric patients with ASMD. These benefits are sustained through at least 24 months of treatment. Olipudase alfa is generally well tolerated; infusion-associated reactions (mostly mild) were the most common treatment-related adverse events. Other warnings and precautions associated with its use include risks of hypersensitivity reactions (including anaphylaxis) and elevated transaminase levels seen in clinical trials, and foetal malformation based on animal studies. All these risks are generally manageable. A gradual dose escalation of olipudase alfa, followed by a maintenance phase, is required to reduce the risks of toxic sphingomyelin catabolites build up, infusion-associated reactions and transient transaminase elevations. SN - 1179-1918 UR - https://www.unboundmedicine.com/medline/citation/37133675/Olipudase_Alfa_in_Non_CNS_Manifestations_of_Acid_Sphingomyelinase_Deficiency:_A_Profile_of_Its_Use_ DB - PRIME DP - Unbound Medicine ER -